Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20604661 | 1.00 | KDM1A (1.00) | KDM1A | |
| SCHEMBL20025743 | 1.00 | KDM1A (1.00) | KDM1A | |
| SCHEMBL22341478 | 0.93 | KDM1A (1.00) | KDM1A | |
| SCHEMBL20025706 | 0.93 | KDM1A (1.00) | KDM1A | |
| SCHEMBL22341472 | 0.93 | KDM1A (1.00) | KDM1A | |
| SCHEMBL20025745 | 0.93 | KDM1A (1.00) | KDM1A | |
| SCHEMBL20025714 | 0.93 | KDM1A (1.00) | KDM1A | |
| SCHEMBL22341476 | 0.93 | KDM1A (0.86) | KDM1A | |
| SCHEMBL22341477 | 0.93 | KDM1A (0.86) | KDM1A | |
| SCHEMBL19095363 | 0.91 | KDM1A (1.00) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423443-B1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2020-08-19 | — | — | EP | claimed |
| EP-3423443-B1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| EP-3423443-B1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2020-08-19 | — | — | EP | disclosed |
| US-10590079-B2 | Cyano-substituted indoles as LSD1 inhibitors | NOVARTIS AG (CH) | 2020-03-17 | — | — | US | disclosed |
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CL) | 2019-10-03 | — | — | US | disclosed |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2019-03-28 | — | — | US | disclosed |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | NOVARTIS AG (CH) | 2019-03-28 | — | — | US | disclosed |
| WO-2018059549-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | NOVARTIS AG (CH) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298715-A1 | IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY | KDM1B, KDM1A, KDM2A | KDM1A 2/4885 |
| US-10590079-B2 | Cyano-substituted indoles as LSD1 inhibitors | KDM1A, KDM1B, KDM3A | KDM1A 1/4885 |
| US-20190092724-A1 | CYANO-SUBSTITUTED INDOLE COMPOUNDS AND USES THEREOF AS LSD1 INHIBITORS | KDM1A, KDM1B, KDM2A | KDM1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.